Lipid Nanoparticles Improve the Uptake of α-Asarone Into the Brain Parenchyma: Formulation, Characterization, In Vivo Pharmacokinetics, and Brain Delivery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ramalingam, P. | - |
dc.contributor.author | Ganesan, P. | - |
dc.contributor.author | Prabakaran, D.S. | - |
dc.contributor.author | Gupta, P.K. | - |
dc.contributor.author | Jonnalagadda, S. | - |
dc.contributor.author | Govindarajan, K. | - |
dc.contributor.author | Vishnu, R. | - |
dc.contributor.author | Sivalingam, K. | - |
dc.contributor.author | Sodha, S. | - |
dc.contributor.author | Choi, D.-K. | - |
dc.contributor.author | Ko, Y.T. | - |
dc.date.available | 2020-11-26T00:40:23Z | - |
dc.date.created | 2020-11-09 | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 1530-9932 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79076 | - |
dc.description.abstract | Treatment of brain-related diseases is one of the most strenuous challenges in drug delivery research due to numerous hurdles, including poor blood-brain barrier penetration, lack of specificity, and severe systemic toxicities. Our research primarily focuses on the delivery of natural therapeutic compound, α-asarone, for the treatment of brain-related diseases. However, α-asarone has poor aqueous solubility, bioavailability, and stability, all of which are critical issues that need to be addressed. This study aims at formulating a lipid nanoparticulate system of α-asarone (A-LNPs) that could be used as a brain drug delivery system. The physicochemical, solid-state properties, stability, and in vitro and in vivo studies of the A-LNPs were characterized. The release of α-asarone from the A-LNPs was prolonged and sustained. After intravenous administration of A-LNPs or free α-asarone, significantly higher levels of α-asarone from the A-LNPs were detected in murine plasma and brain parenchyma fractions, confirming the ability of A-LNPs to not only maintain a therapeutic concentration of α-asarone in the plasma, but also transport α-asarone across the blood-brain barrier. These findings confirm that lipid nanoparticulate systems enable penetration of natural therapeutic compound α-asarone through the blood-brain barrier and may be a candidate for the treatment of brain-related diseases. © 2020, American Association of Pharmaceutical Scientists. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | AAPS PharmSciTech | - |
dc.title | Lipid Nanoparticles Improve the Uptake of α-Asarone Into the Brain Parenchyma: Formulation, Characterization, In Vivo Pharmacokinetics, and Brain Delivery | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000588273700002 | - |
dc.identifier.doi | 10.1208/s12249-020-01832-8 | - |
dc.identifier.bibliographicCitation | AAPS PharmSciTech, v.21, no.8 | - |
dc.identifier.scopusid | 2-s2.0-85094874903 | - |
dc.citation.title | AAPS PharmSciTech | - |
dc.citation.volume | 21 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Ramalingam, P. | - |
dc.contributor.affiliatedAuthor | Ko, Y.T. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | brain distribution | - |
dc.subject.keywordAuthor | lipid nanoparticles | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | stability | - |
dc.subject.keywordAuthor | α-asarone | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.